Insulet Corporation (NASDAQ:PODD) is one of the most promising healthcare stocks according to Wall Street analysts. On June 6, Insulet Corporation (NASDAQ:PODD) released new clinical results for two of its next-generation diabetes management systems, which management described as strong and that bring the company closer to making the systems a reality.
Cherries/Shutterstock.com
The two diabetes systems are Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes. In the first study, dubbed STRIVE pivotal trial, the company compared the current Omnipod 5 with Omnipod 6 and found that the latter improved time in tight range by 7% for type 1 adults and by 5% for type 2 patients. Overall time in range also improved across both groups. The results also show that the new system delivered up to 50% more automated insulin.
Another key finding from STRIVE was that Omnipod 6 performed far better even when patients bolused less. The company explained that this matters because one of the biggest reasons people with diabetes don’t hit their targets is inconsistency in remembering or choosing to manually dose for meals. Omnipod 6 compensates for that gap.
The other study, dubbed EVOLUTION 3, achieved 64% time in range, which is a 12% improvement over baseline. The system also cut total daily insulin from 86 units down to 58 units with no accompanying weight gain, and 86% of participants reported being satisfied or highly satisfied with the system.
Insulet noted that both devices remain investigational and have not yet been cleared by the FDA. It added that following EVOLUTION 3, the company has already enrolled the first patients in the next trial for the FCL system, dubbed EVOLVE, and is targeting a commercial launch in 2028.
Insulet Corporation (NASDAQ:PODD) is a medical device company. It specializes in insulin delivery systems for people with diabetes and its flagship product is the Omnipod insulin management system.
While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.
Disclosure: None. Follow Insider Monkey on Google News.